Publications

Original Research:

82. Rimal B, Lippincott CK, Panthi CM, Xie Y, Keepers TR, Alley MRK, Lamichhane G. Efficacy of epetraborole against Mycobacteroides abscessus in a mouse model of lung infection. Antimicrobial Agents and Chemotherapy. 2024. e0064824. PMID: 39016592. Click here to access this paper.


81. Ignatius EH, Rimal B, Panthi CM, Belz DC, Lippincott CK, Deck DH, Serio AW, Lamichhane G. Efficacies of omadacycline + amikacin + imipenem and an all-oral regimen omadacycline + clofazimine + linezolid in a mouse model of M. abscessus lung disease. mSphere. 2024. e0038124. PMID: 38980071. Click here to access this paper.

 

80. Dartois V, Bonfield TL, Boyce JP, Daley CL, Dick T, Gonzalez-Juarrero M, Gupta S, Kramnik I, Lamichhane G, Laughon BE, Lore NI, Malcolm KC, Olivier KN, Tuggle KL, Jackson M. Preclinical murine models for the testing of antimicrobials against Mycobacterium abscessus pulmonary infections: Current practices and recommendations. Tuberculosis. 2024. Click here to access this paper.


79. Rimal B, Panthi CM, Xie Y, Belz DC, Ignatius EH, Lippincott CK, Deck DH, Serio AW, Lamichhane G. Efficacies of three drug regimens containing omadacycline to treat Mycobacteroides abscessus disease. Tuberculosis. 2024. 146:102482. doi: 10.1016/j.tube.2024.102482. PMID 38364332. Click here to access this paper.


78. Wazahat R, Juneja P, Chauhan V, Zaidi R, Lamichhane G, Singh UB, Haider M, Kumar P. A strip-based assay for detection of CrfA enzyme activity to differentiate Mycobacterium tuberculosis and non-tuberculous mycobacteria. J Microbiol Methods. 2023. 211:106781. DOI 10.1016/j.mimet.2023.106781. PMID 37437716


77. Rimal B, Nicklas DA, Panthi CM, Lippincott CK, Belz DC, Ignatius EH, Deck DH, Serio AW, Lamichhane G. Efficacy of omadacycline containing regimen in a mouse model of pulmonary M. abscessus disease. mSphere. 2023. PMID 36912629. Click here to access this paper.


76. Ochsner UA, De Groote MA, Jarvis TC, Liu H, Youmans T, Hoang T, Ribble W, Day J, Li W, Pearce C, Walz A, Panthi CM, Rimal B, Stevens CM, Zgurskaya HI, Jackson M, Ordway D, Gonzalez-Juarrero M, Sun X, Lamichhane G, Mason C. Microbiological profile, preclinical pharmacokinetics and efficacy of CRS0393, a novel antimycobacterial agent targeting MmpL3. 2022. Tuberculosis. 138: 102288, DOI: 10.1016/j.tube.2022.102288. PMID 36470124. Click here to access this paper. 


75. Sriram D, Wahi R, Maggioncalda EC, Panthi CM, Lamichhane G. Clofazimine as a comparator for preclinical efficacy evaluations of experimental therapeutics against M. abscessus infection in mice. 2022. Tuberculosis.137:102268. PMID 36228452  DOI: 10.1016/j.tube.2022.102268 Click here to access this paper.


74. Ntombela T, Seupersad A, Maseko S, Ibeji CU, Tolufashe G, Maphumulo SI, Naicker T, Baijnath S, Maguire GEM, Govender T, Lamichhane G, Honarparvar B, Kruger HG. Mechanistic insight on the inhibition of D, D-carboxypeptidase from M. tuberculosis by β-lactam antibiotics: an ONIOM acylation study. 2022. J Biomol Struct Dyn. 40(17):7645-7655. doi: 10.1080/07391102.2021.1899052. PMID: 33719919. Click here to access this paper.


73. Batchelder HR, Zandi TA, Kaushik A, Naik A, Story-Roller E, Maggioncalda EC, Lamichhane G, Nuermberger EL, Townsend CA. Structure-activity relationship of penem antibiotic sidechains for use against mycobacteria reveal highly active compounds. 2022. ACS ID. PMID 35916356. Click here to access this paper.


72. Rimal B, Senzani S, Ealand C, Lamichhane G, Kana B, Kim SJ. Peptidoglycan compositional analysis of Mycobacterium smegmatis using high-resolution LC-MS. 2022. Scientific Reports. PMID 35773428. https://doi.org/10.1038/s41598-022-15324-1 Click here to access this paper.


71. Rimal B, Batchelder HR, Story-Roller E, Panthi CM, Tabor C, Nuermberger EL, Townsend CA, Lamichhane G. T405, a new penem, exhibits in vivo efficacy against M. abscessus and synergy with β-lactams imipenem and cefditoren. 2022. Antimicrobial Agents and Chemotherapy. PMID 35638855. Open Access. Click here to access this paper. If you cannot access, email me and I will get you a copy. 


70. Ahmad N, Dugad S, Chauhan V, Ahmed S, Sharma K, Kachhap S, Zaidi R, Bishai WR, Lamichhane G*, Kumar P*. Allosteric cooperation in ß-lactam binding to a non-classical transpeptidase. 2022. eLife. Apr 27. 11:e73055. PMID 35475970.  *co-corresponding author. Click here to access the paper.


69. Galanis C, Maggioncalda EC, Kumar P, Lamichhane G. Glby, encoded by MAB_3167c, is required for in vivo growth of M. abscessus and exhibits mild β-lactamase activity. 2022. Journal of Bacteriology. Apr 5:e0004622. PMID. 35380462  doi: 10.1128/jb.00046-22


68. De Jager V, Gupte N, Nunes S, Barnes GL, van Wijk RC, Mostert J, Dorman SE, Abulfathi AA, Upton C, Faraj A, Nuermberger E, Lamichhane G, Svensson EM, Simonsson U, Diacon AH, Dooley KE and the COMRADE study team. Early bactericidal activity of meropenem plus clavulanate (+/- rifampin) for TB: The COMRADE trial. 2022. AJRCCM. PMID 35258443. DOI: 10.1164/rccm.202108-1976OC. 


67. Kumar G, Galanis C, Batchelder HR, Townsend CA, Lamichhane G. Penicillin Binding Proteins and β-lactamases of Mycobacterium tuberculosis: Reexamination of the Historical Paradigm. 2022. mSphere. PMID 35196121. doi: 10.1128/msphere.00039-22. Open Access from mSphere website


66.  Nicklas DA, Maggioncalda EC, Story-Roller E, Eichelman B, Tabor C, Serio AW, Keepers TR, Chitra S, Lamichhane G. Potency of omadacycline against Mycobacteroides abscessus clinical isolates in vitro and in a mouse model of pulmonary infection. 2021. Antimicrobial Agents and Chemotherapy. PMID 34662184 


65. Galanis C, Maggioncalda EC, Kumar G, Lamichhane G. Glby is a PBP with b-lactamase activity and is required for in vivo viability of M. abscessus. 11 July 2021. Biorxiv.  https://biorxiv.org/cgi/content/short/2021.07.11.451952v1 


64. Jadav R, Gallardo-Macias R, Kumar G, Daher SS, Kaushik A, Bigelow KM, Nuermberger EL*, Lamichhane G*, Freundlich JS*. Assessment of carbapenems in a mouse model of Mycobacterium tuberculosis infection. 2021. PLoS One. 16 (5) e0249841. PMID 33939697 


63. Ntombela T, Seupersad A, Maseko SB, Ibeji CU, Tolufashe GF, Maphumolo SI, Naicker T, Bajinath S, Maguire GEM, Govender T, Lamichhane G, Honarparvar B, Kruger HG. Mechanistic insight on the inhibition of D,D-carboxypeptidase from Mycobacterium tuberculosis by β-lactam antibiotics: an ONIOM acylation study. 2021. J Biomol Struct Dyn.  . PMID 33719919

62. Story-Roller E, Galanis C, Lamichhane G.  β-lactam combinations that exhibit synergy against Mycobacteroides abscessus clinical isolates. 2021. Antimicrobial Agents and Chemotherapy. PMID 33361310

61. Batchelder HR, Story-Roller E, Lloyd EP, Kaushik A, Bigelow KM, Maggioncalda EC, Nuermberger EL, Lamichhane G, Townsend CA. Development of a penem antibiotic against Mycobacteroides abscessus. 2020. Communications Biology. 3, 741. PMID 33288821 

60. Maggioncalda EC, Story-Roller E, Mylius J, Illei P, Basaraba RJ, Lamichhane G. A mouse model of pulmonary Mycobacteroides abscessus infection. 2020. Scientific Reports. 10. https://rdcu.be/b2i1h PMID 32111900

59. Story-Roller E, Maggioncalda EC, Lamichhane G. Synergistic efficacy of β-lactam combinations against Mycobacterium abscessus pulmonary infection in mice. 2019. Antimicrobial Agents and Chemotherapy. 63(8) PMID 31109979

58. Sabe VT, Tolufashe GF, Ibeji CU, Maseko SB, Govender T, Maguire GEM, Lamichhane G, Honarparvar B, Kruger HG. 2019. J Mol Model. 25(11)328. PMID 31656981 

57. Thota N, Makam P, Rajbongshi KK, Nagiah S, Abdul NS, Chuturgoon AA, Kaushik A, Lamichhane G, Somboro AM, Kruger HG, Govender T, Naicker T, Arvidsson PI. N-Trifluoromethylthiolated sulfonimidamides and sulfoximines: Anti-microbial, anti-mycobacterial and cytotoxic activity. 2019. ACS Medicinal Chemistry Letters. 10(10):1457-1461. PMID 31620233

56. Ibeji CU, Lawal MM, Tolufashe GF, Govender T, Naicker T, Maguire GEM, Lamichhane G, Kruger HG, Honarparvar B. The driving force for the acylation of β-lactam antibiotics by L,D-transpeptidase 2: Quantum Mechanics/Molecular Mechanics (QM/MM) Study. 2019. Chemphyschem. PMID 30969480

55. Story-Roller E, Maggioncalda EC, Lamichhane G. Select β-lactam combinations exhibit synergy against Mycobacterium abscessus in vitro. 2019. Antimicrobial Agents and Chemotherapy. 63 (4) e02613-18 PMID 30745389 

54. Singh UB, Das R, Shrestha P, Bala K, Pandey P, Verma SK, Gautam H, Story-Roller E, Lamichhane G, Guleria R. Compromised longevity due to Mycobacterium abscessus pulmonary disease in lungs scarred by tuberculosis. 2019. Access Microbiology. DOI 10.1099/acmi.0.000003 

53.  Kaushik A, Ammerman NC, Lee J, Olumide M, Kreiswirth BN, Lamichhane G, Parrish NM, Nuermberger EL. In vitro activity of the new β-lactamase inhibitors relebactam and vaborbactam in combination with β-lactams against Mycobacterium abscessus complex clinical isolates. 2019. Antimicrobial Agents and Chemotherapy. 63 (3) e02623-18 PMID 30642943

52.  Tolufashe GF, Sabe VT, Ibeji CU, Lawal MM, Govender T, Maguire GEM, Lamichhane G, Kruger HG, Honarparvar B. Inhibition of L,D-transpeptidase 5 in presence of the β-lactams using ONIOM method. 2019. Journal of Molecular Graphics and Modeling. 87. 204-210. PMID 30554066

51.  Ibeji CU, Tolufashe GF, Ntombela T, Govender T, Maguire GEM, Lamichhane G, Kruger HG, Honarparvar B. The catalytic role of water in the binding site of L,D-transpeptidase 2 within acylation mechanism: A QM/MM (ONIOM) modeling. 2018. Tuberculosis. 113, 222-230. PMID 30514506

50.  Tolufashe GF, Sabe VT, Ibeji CU, Ntombela T, Govender T, Maguire GEM, Kruger HG, Lamichhane G, Honarparvar B. Structure and function of L,D- and D,D-transpeptidase family enzymes from Mycobacterium tuberculosis. 2018. Current Medicinal Chemistry. PMID 30501595

49.  Schwartz M, Fisher S, Story-Roller E, Lamichhane G, Parrish N. Activities of dual combinations of antibiotics against multi-drug resistant non-tuberculous mycobacteria recovered from patients with cystic fibrosis. 2017. Microbial Drug Resistance. PMID 29368988.

48.  Azzali E, Machado D, Kaushik A, Vacondio F, Flisi S, Cabassi CS, Lamichhane G, Viveiros M, Constantito G, Pieroni M. Substituted N-phenyl-5-(2-(phenylamino)thiazol-4-yl)isoxazole-3-carboxamides Are Valuable Antitubercular Candidates that Evade Innate Efflux Machinery. 2017. Journal of Medicinal Chemistry. PMID 28749666

47.  Kumar P, Chauhan V, Silva JRA, Lameira J, d’Andrea F, Li S, Ginell SL, Freundlich JS, Alves CN, Bailey S, Cohen KA, Lamichhane G. Mycobacterium abscessus L,D-transpeptidases are susceptible to inactivation by carbapenems and cephalosporins but not penicillins. Antimicrobial Agents and Chemotherapy. 2017. 61 (10) e00866-17 PMID 28760902

46.  Fakhar Z, Govender T, Maguire GEM, Lamichhane G, Walker RC, Kruger HG, Honarparvar B. Differential flap dynamics in L,D-transpeptidase 2 from Mycobacterium tuberculosis revealed by molecular dynamics. 2017. Molecular Biosystems. PMID 28480928

45.  Bianchet MA, Pan Y, Basta LAB, Saaverda H, Lloyd EP, Kumar P, Mattoo R, Townsend CA, Lamichhane G.  Structural insight into the mechanism of inhibition of Mycobacterium tuberculosis l,d-transpeptidase-2 by biapenem and tebipenem. 2017. BMC Biochemistry. PMID 28545389

44.  Kaushik A, Ammerman NC, Tasneen R, Story-Roller E, Dooley KE, Dorman SE, Nuermberger E, Lamichhane G. In vitro and in vivo activity of biapenem against drug-susceptible and rifampin-resistant M. tuberculosis. 2017. Journal of Antimicrobial Chemotherapy. PMID 28575382

43.  Njire M, Wang N, Wang B, Tan Y, Cai X, Liu Y, Mugweru J, Guo J, Hameed HMA,Tan S,Liu J, Yew WW, Nuermberger EL, Lamichhane G, Liu J, Zhang T. Pyrazinoic Acid Inhibits a Bifunctional Enzyme in Mycobacterium tuberculosis. 2017. Antimicrobial Agents and Chemotherapy. PMID 28438933

42.  Fakhar Z, Govender T, Lamichhane G, Maguire GEM, Kruger HG, Honarparvar B. Computational model for the acylation step of the β-lactam ring: potential application for L,D-transpeptidase 2 in Mycobacterium tuberculosis. Journal of Molecular Structure. 2017. 1128; 94-102.

41.  Kaushik A, Gupta C, Fisher S, Story-Roller E, Galanis C, Parrish N, Lamichhane G. Combinations of avibactam and carbapenems exhibit enhanced potencies against drug-resistant Mycobacterium abscessus. 2017. Future Microbiology. 12 (6): 473-480. PMID 28326811

40.  Dey RJ, Dey B, Zheng Y, Cheung LS, Zhou J, Sayre D, Kumar P, Guo H, Lamichhane G, Sintim HO, Bishai WR. Inhibition of innate immune cytosolic surveillance by an M. tuberculosis phosphodiesterase. Nature Chemical Biology. 2017. 13; 210-217. PMID 28106876

39.  Mattoo R, Lloyd EP, Kaushik A, Kumar P, Brunelle JL, Townsend CA, Lamichhane G. LdtMav2, a nonclassical transpeptidase and susceptibility of Mycobacterium avium to carbapenems. 2017. Future Microbiology. 12(7): 595-607. PMID 28555497

38.  Kumar P, Kaushik A, Bell D, Xia F, Stevens RL, Lamichhane G. Mutation in an unannotated protein confers carbapenem resistance in Mycobacterium tuberculosis. 2017. Antimicrobial Agents and Chemotherapy. 61(3)e02234-16. PMID 98069655

37.  Kumar P, Kaushik A, Lloyd EP, Li SG, Mattoo R, Ammerman NC, Lloyd DT, Perryman AL, Ekins S, Ginell SL, Townsend CA, Freundlich JS, Lamichhane G. New antibacterials targeting non-classical transpeptidases. Nature Chemical Biology. 2017. 13; 54-61. PMID 27820797. 

36.  Kaushik A, Heuer AM, Bell DT, Culhane JC, Ebner DC, Parrish N, Ippoliti JT, Lamichhane G. An evolved oxazolidinone with selective potency against Mycobacterium tuberculosis and gram positive bacteria. 2016. Bioorganic & Medicinal Chemistry Letters.2016. 26(15); 3572-6. PMID 27329794

35.  Pelly S, Winglee K, Xia FF, Stevens RL, Bishai WR, Lamichhane G. REMap: Operon Map of M. tuberculosis based on RNA Sequence Data. 2016. Tuberculosis. 2016. 99; 70-80. PMID 27450008 

34.  Zhang T, Makafe G, Cao Y, Tan Y, Julius M, Liu Z, Wang C, Njire M, Cai X, Liu T, Wang B, Pang W, Tan S, Zhang B, Yew W, Lamichhane G, Gua J. Oxazolidinone Resistance in Mycobacterium tuberculosis: What is the Role of Cys154Arg Mutation in the Ribosomal Protein L3? 2016. Antimicrobial Agents and Chemotherapy. 60(5); 3202-6. PMID 26953211

33.  Fakhar Z, Naiker S, Alvez CN, Govender T, Maguire GEM, Lameira J, Lamichhane G, Kruger HG, Honarparvar B. A comparative modelling and molecular docking study on Mycobacterium tuberculosis targets involved in peptidoglycan biosynthesis. Journal of Biomolecular Structure & Dynamics. 2016. Apr 4:1-19. PMID 26612108 

32.  Basta LAB, Ghosh A, Pan Y, Jean J, Lloyd E, Townsend C, Lamichhane G*, Bianchet M*. *Co-corresponding author. Loss of a Functionally and Structurally Distinct ld-Transpeptidase, LdtMt5, Compromises Cell Wall Integrity in Mycobacterium tuberculosis. 2015. Journal of Biological Chemistry. 290: 25670-85. PMID 26304120

31.  Kaushik A, Pandey P, Makkar N, Parrish N, Singh U, Lamichhane G. Carbapenems and Rifampicin Exhibit Synergy  Against Mycobacterium tuberculosis and Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy. 2015. 59(10), 3561-67. PMID 26259792.

30. Alyahya SA, Nolan ST, Smith C, Bishai WR, Sadoff J and Lamichhane G. Immunogenicity without efficacy of an adenoviral tuberculosis vaccine in a stringent mouse model for immunotherapy during treatment. PLoS ONE. 2015. 10(5): e0127907. PMID: 25996375

29.  Silva JR, Bishai WR, Govender T, Lamichhane G, Maguire GE, Kruger HG, Lameira J, Alves CN. Targeting the cell wall of Mycobacterium tuberculosis: A molecular modelling investigation of the interaction of imipenem and meropenem with LD-transpeptidase 2.J Biomol Struct Dyn. 2015. 12:1-34. PMID: 25762064

28.  Moraes GL, Gomes GC, DeSousa PRM, Alves CN, Govender T, Kruger HG, Maguire GE, Lamichhane G, Lameira J. Structural and Functional Features of Enzymes of M. tuberculosis Peptidoglycan Biosynthesis as Targets for Drug Development. Tuberculosis. 2015. PMID: 25701501

27.  Dutta NK, Bandyopadhyay N, Veeramani B, Lamichhane G, Karakousis PC, Bader JS. Systems Biology-Based Identification of Mycobacterium tuberculosis Persistence Genes in Mouse Lungs. mBio. 2014; 5 (1), e01066-13. PMID 24549847

26.  Schoonmaker MK, Bishai WR, Lamichhane G. Non-classical cross-linking of the peptidoglycan of Mycobacterium tuberculosis is required for cell morphology, virulence and resistance to β-lactams and glycopeptides. Journal of Bacteriology. 2014; 196 (7), 1394-402.PMID 24464457

25.  Lamichhane G, Arnvig KB, McDonough KA. Definition and annotation of (myco)bacterial non-coding RNA. Tuberculosis. 2013; S1472-9792. PMID 23291152.

24.  Erdmeli SB, Gupta R, Bishai WR, Lamichhane G, Amzel LM, Bianchet MA. Targeting the Cell Wall of Mycobacterium tuberculosis: Structure and Mechanism of LD-transpeptidase 2. Structure. 2012; 20(12), 2013-15. PMID: 23103390.

23.  Sarker M, Talcott C, Madrid P, Chopra S, Bunin BA, Lamichhane G, Freundlich JS, Ekins S. Combining Cheminformatics Methods and Pathway Analysis To Identify Molecules With Whole-Cell Activity Against Mycobacterium tuberculosis. PharmRes, 2012; 8, 2115-27. PMID: 22477069

22.  Pelly S, Bishai WR, Lamichhane G. A screen for non-coding RNA in Mycobacterium tuberculosis reveals a cAMP-responsive RNA that is expressed during infection. Gene. 2012. 500(1):85-92. PMID: 22446041

21.  Lamichhane G, Freundlich JS, Ekins S, Wickramaratne N, Nolan ST, Bishai WR. Essential Metabolites of M. tuberculosis and their Mimics. mBio. 2011; 2(1):e00301-10.  PMID: 21285434.

20.  Wolschendorf F, Ackart D, Shrestha TB, Hascall-Dove L, Nolan S, Lamichhane G, Wang Y, Bossmann SH, Basaraba RJ, Niederweis M. Copper resistance is essential for virulence of M. tuberculosis. PNAS. 2011; 108(4):1621-6. PMID: 21205886

19.  Nolan ST, Lamichhane G. Protective efficacy of BCG overexpressing an LD-transpeptidase against M. tuberculosis infection. PLoS One. 2010; 5(10): e13773. PMID: 21048936.

18.  Converse PJ, Eisenach KD, Theus SA, Nuermberger EL, Tyagi S, Ly LH, Geiman DE, Guo H, Nolan ST, Akar NC, Klinkenberg LG, Gupta R, Lun S, Karakousis PC, Lamichhane G, McMurray DN, Grosset JH, Bishai WR. The impact of mouse passaging of Mtb strains prior to virulence testing in mouse and guinea pig aerosol models. PLoS One. 2010; 5, e10289. PMID: 20422019

17.  Gupta R, Lavollay M, Mainardi J, Arthur M, Bishai WR, Lamichhane G. The Mycobacterium tuberculosis gene, ldtMt2, encodes a non-classical transpeptidase required for virulence and resistance to amoxicillin. Nature Medicine. 2010; 16, 466-9. PMID:20305661

16.  Olaleye O, Raghunand TR, Bhat S, He J, Tyagi S, Lamichhane G, Gu P, Zhou J, Zhang Y, Grosset J, Bishai WR, Liu JO. Methionine Aminopeptidases from Mtb as novel antimycobacterial target. Chem Biol. 2010; 17, 86. PMID: 20142044

15.  Dutta NK, Mehra S, Didier PJ, Roy CJ, Doyle LA, Alvarez X, Ratterree M, Be NA, Lamichhane G, Jain SK, Lacey MR, Lackner AA, Kaushal D.  M. tb genes required for growth in primates. Journal of Infectious Diseases. 2010; 11, 1743-52. PMID: 20394526

14.  Lamichhane G. Novel targets in M. tuberculosis: search for new drugs. Trends in Molecular Medicine. 2010; PMID: 21071272

13.  Davis SL, Be NA, Lamichhane G, Nimmagadda S, Pomper MG, Bishai WR, Jain SK. Bacterial thymidine kinase as a non-invasive imaging reporter for M. tuberculosis in live animals. PLoS One. 2009; e6297. PMID:19606217

12.  Agarwal N, Lamichhane G, Gupta R, Nolan S, Bishai W. R. cAMP intoxication of macrophages by a  M. tuberculosis adenylate cyclase. Nature. 2009; 460, 98-102. PMID:19516256

11.  Converse PJ, Karakousis PC, Klinkenberg LG, Kesavan AK, Ly LH, Allen SS, Grosset JH, Jain SK, Lamichhane G, Manabe YC, McMurray DN, Nuermberger EL, Bishai WR. Role of the dosR-dosS two-component regulatory system in M. tuberculosis virulence in animal models. Infect Immun. 2009; 77(3):1230-7. PMID:19103767

10.  Alahari A, Alibaud L, Trivelli X, Gupta R, Lamichhane G, Reynolds RC, Bishai WR, Guerardel Y, Kremer L. Mycolic acid methyltransferase, MmaA4, is necessary for thiacetazone susceptibility in Mycobacterium tuberculosis. Mol Microbiol. 2009; 71(5):1263-77. PMID:19183278

9.    Be NA, Lamichhane G, Grosset J, Tyagi S, Cheng QJ, Kim KS, Bishai WR, Jain SK. Murine model to study the invasion and survival of M. tuberculosis in the central nervous system. Journal of Infectious Diseases. 2008; 198:1520-8. PMID: 18956986.

8.    Jain S. K., Lamichhane G., Nimmagadda S., Pomper M. G., and Bishai W. R. Antibiotic Treatment of Tuberculosis: Old Problems, New Solutions. Microbe. 2008; Vol 3, 285-292. 

7.    Lamichhane G., and Bishai W. R. Defining the Survivasome of Mycobacterium tuberculosis. Nature Medicine. 2007; Vol 13. No. 3. 280-282. PMID: 17342137.

6.    Jain S. K., S. Moises Hernandez-Abanto, Qi-Jian Cheng, Prabhpreet Singh, Lan H. Ly, Lee G. Klinkenberg, Norman E. Morrison, Paul J. Converse, Eric Nuermberger, Jacques Grosset, David N. McMurray, Petros Karakousis, Lamichhane G, and W R. Bishai. 'Accelerated detection of M tuberculosis genes essential for bacterial survival in guinea pigs compared with mice. Journal of Infectious Diseases. 2007; 195, 1634-42. PMID: 17471433

5.    Lamichhane G., Tirumalai R., Morrison N. E., Woolwine S. C., Tyagi S., Kandavelou K., and Bishai W. R. Inactivation of mpa leads to growth attenuation and provides protection against virulent M. tuberculosis. Journal of Infectious Diseases. 2006; 194, 1233-1240. PMID:17041849.

4.    Jain S. K., Paul-Satyaseela M., Lamichhane G., Kim K. S., & Bishai W. R. Mtb invasion and traversal across an in vitro human blood brain barrier as a pathogenic mechanism for CNS TB. Journal of Infectious Diseases.  2006; 193, 1287-95. PMID:16586367.

3.    Lamichhane G., Tyagi S., and Bishai W. R. Designer arrays for defined mutant analysis to detect genes essential for survival of Mycobacterium tuberculosis in mouse lungs. Infect Immun. 2005. Vol 73, 2533-40. PMID:15784600.

2.    Karakousis P., Yoshimatsu T., Lamichhane G., Woolwine S. C., Nuermberger E. L., Grosset J., and Bishai, W. R. Dormancy phenotype displayed by extracellular M. tuberculosis within artificial granulomas in mice. Journal of Experimental Medicine. 2004; 200, 1-12. PMID: 15353557.

1.    Lamichhane G, Zignol M, Blades NJ, Geiman DE, Dougherty A, Grosset J, Broman KW, Bishai WR. A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: application to M. tuberculosis. Proc Natl Acad Sci USA. 2003; 100:7213-8. PMID: 12775759.

Invited Reviews:

8. Lippincott CK, Lamichhane G. Case Commentary: Dual β-lactam as part of regimen to treat Mycobacterium abscessus lung disease. 2024. AAC. PMID 38837394  

7. Story-Roller E, Maggioncalda EC, Cohen KA, Lamichhane G. Mycobacterium abscessus and β-lactams: Emerging Insights and Potential Opportunities. 2018. Frontiers in Microbiology. PMID 30319581

6. Story-Roller E, Lamichhane G. Have we realized the full potential of β-lactams for treating drug-resistant TB? 2018. IUBMB Life. PMID 29934998     

5. Lamichhane G, Grosset JH. Emerging Therapies. In: Grosset JH, Chaisson RE, Eds.  Handbook of Tuberculosis. Adis/Springer Nature, 2017. Cham, Switzerland.

4.    Jaganath D, Lamichhane G, Shah M. Carbapenems against Mycobacterium tuberculosis: A review of the evidence. The International Journal of Tuberculosis and Lung Disease. 2016. Vol. 20, Number 11, 1436-1447. PMID 27776583

3.    Islam MM, Hameed HMA, Mugweru J, Chhotaray C, Wang C, Tan Y, Liu J, Li X, Tan S, Ojima I, Yew WW, Nuermberger E, Lamichhane G, Zhang T. Drug resistance mechanisms and novel drug targets for tuberculosis therapy. Journal of Genetics & Genomics. 2016. PMID 28117224

2.    Lamichhane G. Mycobacterium tuberculosis response to stress from reactive oxygen and nitrogen species. Frontiers in Microbiology. 2011; 2:176. PMID: 21904537

1.    Yoder M, Lamichhane G, Bishai WR. Cavitary Pulmonary Tuberculosis: The Holey Grail of Disease Transmission. Current Science, 2004; Vol. 86, 101-108.

Book Chapters:

    

3.    Kumar P, Singh U, Lamichhane G, Story-Roller E. Repurposing of carbapenems for treatment of drug-resistant tuberculosis. In 'Mycobacterium tuberculosis: Molecular Infection Biology, Pathogenesis, Diagnostics and New Interventions.' Springer. 2020. Chapter 26.

2.    Lamichhane G. Peptidoglycan in Bacteria. McGraw Hill. 2017.

1.    Lamichhane G, Grosset JH. Emerging Therapies. In Handbook of Tuberculosis. Editors Grosset JH, Chaisson RE. Springer International Publishing. Switzerland. 2017.191-218

Patents: